Background
This study was designed to investigate the dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and recommended dose (RD) of weekly docetaxel treatment in patients with relapsed ovarian cancer after the administration of platinum/paclitaxel/irinotecan.
Methods
Patients were enrolled on the basis of inclusion and exclusion criteria. Docetaxel was administered intravenously over a 60-min period on days 1, 8, and 15. Four dosage levels, 30, 35, 40, and 45 mg/m2, were employed, and the dosage was escalated from level 1 to level 4. DLT criteria were established, and the DLT was used as the criterion for deciding the MTD and RD.
Results
Twelve patients were enrolled. No grade 3/4 hematological toxicities were manifested at any dosage level. Grade 3/4 nonhematologic toxicities were manifested at level 4, consisting of fatigue/asthenia in 2 patients and neuropathy/sensory toxicity in 1 patient. Level 4 (45 mg/m2) was thus judged to be the MTD, and the RD was concluded to be one level lower, i.e., level 3 (40 mg/m2).
Conclusions
It was concluded that the RD for weekly docetaxel therapy is 40 mg/m2 per week in patients with relapsed ovarian cancer after the administration of platinum/paclitaxel/irinotecan.
Similar content being viewed by others
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Terauchi, F., Hirano, T., Taoka, H. et al. Weekly docetaxel for patients with platinum/paclitaxel/irinotecan-resistant relapsed ovarian cancer: a phase I study. Int J Clin Oncol 8, 348–351 (2003). https://doi.org/10.1007/s10147-003-0351-7
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10147-003-0351-7